Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

40.86USD
16 Oct 2017
Change (% chg)

$-0.15 (-0.37%)
Prev Close
$41.01
Open
$40.97
Day's High
$40.99
Day's Low
$40.64
Volume
588,475
Avg. Vol
605,580
52-wk High
$44.53
52-wk Low
$37.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $98,874.82
Shares Outstanding(Mil.): 2,459.32
Dividend: 0.50
Yield (%): 6.08

Financials

  Industry Sector
P/E (TTM): -- 31.52 16.83
EPS (TTM): -- -- --
ROI: -- 14.97 10.92
ROE: -- 16.23 14.52

GlaxoSmithKline's shingles vaccine gets approval in Canada

Canadian health regulators have approved GlaxoSmithKline's key shingles vaccine, the company said on Friday.

Oct 13 2017

GlaxoSmithKline's shingles vaccine gets approval in Canada

Oct 13 Canadian health regulators have approved GlaxoSmithKline's key shingles vaccine, the company said on Friday.

Oct 13 2017

BRIEF-Glaxosmithkline says ‍shingles vaccine approved in Canada

* ‍SHINGRIX HAS BEEN APPROVED IN CANADA FOR PREVENTION OF SHINGLES (HERPES ZOSTER) IN PEOPLE AGED 50 YEARS OR OLDER​

Oct 13 2017

Breakingviews - Pfizer and Glaxo may find romance over the counter

LONDON (Reuters Breakingviews) - Painkillers and pile cream: these are either the recipe for a terrible night in, or a potentially good corporate deal. Pfizer, the $215 billion U.S. drugmaker, has tasked investment banks with looking into a spinoff or sale of its consumer-goods division, which makes Advil and Preparation H. New GlaxoSmithKline boss Emma Walmsley would be well placed to offer a home.

Oct 10 2017

UPDATE 3-Two-year Brexit transition is assured, UK PM May tells business chiefs - source

LONDON, Oct 9 Prime Minister Theresa May told business leaders on Monday that they could be certain there would be a two-year transition period after Britain's exit from the European Union, a source told Reuters.

Oct 09 2017

Drug industry gives up legal battle over new UK cost curbs

LONDON Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review.

Oct 05 2017

UPDATE 1-Drug industry gives up legal battle over new UK cost curbs

LONDON, Oct 5 Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review.

Oct 05 2017

Drug industry fails to win judicial review of new UK cost curbs

LONDON, Oct 4 Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 mln) annually no longer get automatic funding.

Oct 04 2017

BRIEF-GlaxoSmithKline receives approval for Benlysta in Japan for treatment of systemic lupus erythematosus

* ‍JAPANESE MHLW APPROVED BENLYSTA FOR TREATMENT OF ADULT PATIENTS WITH SLE WHO ARE INADEQUATE RESPONDERS TO EXISTING THERAPIES​ Further company coverage:

Sep 27 2017

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 25 2017

Competitors

Earnings vs. Estimates